---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-002784"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:55:53.820808+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# Silexion Q2 net loss $2.5M, cash $3.5M; SIL204 shows up to 97% inhibition across KRAS cancers

## Summary
- Net loss $2.5M for Q2 2025 vs $1.5M in Q2 2024; operating expenses up 64.3% to $2.3M.
- Cash $3.5M at June 30, 2025 (up from $1.2M at Dec 31, 2024); warrant exercise raised ~$1.8M in July.
- Preclinical: SIL204 achieved 94% inhibition in pancreatic, 90% in colorectal, up to 97% in KRAS Q61H pancreatic cancer cells.
- Strategic collaboration with Catalent for formulation development; Phase 2/3 trial on track for H1 2026.
- Nasdaq listing maintained after 1-for-15 reverse split and panel decision; pursuing $2.5M equity threshold.

## SEC filing metadata
- accession: 0001178913-25-002784
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325002784/0001178913-25-002784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325002784/zk2533609.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-002784
- JSON: https://secwatch.observer/filing/0001178913-25-002784.json
- Plain text: https://secwatch.observer/filing/0001178913-25-002784.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.